We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-14.72%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$9.59M
AUM Growth
-$434M
Cap. Flow
-$279M
Cap. Flow %
-2,907.54%
Top 10 Hldgs %
47.01%
Holding
85
New
15
Increased
1
Reduced
62
Closed
7

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$2.17M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.24M
3
BNTX icon
BioNTech
BNTX
+$588K
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$408K
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$180K

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$16.7M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$16.6M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$15.2M
4
PTCT icon
PTC Therapeutics
PTCT
+$14.4M
5
AMGN icon
Amgen
AMGN
+$13.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.54%
2 Miscellaneous 0.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LEGN icon
76
Legend Biotech
LEGN
$3.99B
$4.5K 0.05%
248
-4,252
-94% -$180K
TSVT
77
DELISTED
2seventy bio
TSVT
$3.67K 0.04%
48
-3,618
-99% -$49.3K
NKTX icon
78
Nkarta
NKTX
$197M
– –
-10,034
Closed -$209K
ORIC icon
79
Oric Pharmaceuticals
ORIC
$1.43B
– –
-176,217
Closed -$905K
VRTX icon
80
Vertex Pharmaceuticals
VRTX
$139B
– –
-25,122
Closed -$3.23M
HARP
81
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
– –
-15,145
Closed -$2.77M
GBT
82
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-151,800
Closed -$1.64M
TPTX
83
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
– –
-14,093
Closed -$8.68M
BHVN
84
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-130,900
Closed -$9.29M
1 2 3
4

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q2 2022 Portfolio in Review

As of Q2 2022, International Biotechnology Trust held 85 positions worth $9.59M, down 98% from $443M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

International Biotechnology Trust withdrew a net $279M in Q2 2022, closing 7 positions and reducing 62 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $9.29M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, International Biotechnology Trust opened a new position in Biogen worth $52K.

  • International Biotechnology Trust's largest Q2 2022 buy was Biogen: 10,606 shares worth $52K.
  • International Biotechnology Trust added most to Regeneron Pharmaceuticals in Q2 2022, an estimated $1.24M increase.
  • International Biotechnology Trust's biggest Q2 2022 reduction was Incyte, cutting an estimated $16.7M.
  • International Biotechnology Trust fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q2 2022, selling an estimated $9.29M.
  • International Biotechnology Trust's ten largest holdings make up 47% of its $9.59M portfolio in Q2 2022.
  • International Biotechnology Trust opened 15 new positions and closed 7 in Q2 2022.
  • International Biotechnology Trust's portfolio value fell 98% quarter-over-quarter to $9.59M.

Based on International Biotechnology Trust's 13F filing for Q2 2022, filed 16 Aug 2022.